GLP-1 Drugs May Improve Brain Outcomes After Aneurysm Treatment in Diabetic Patients | Research

The takeaway

GLP-1 RA use was associated with improved clinical outcomes after endovascular treatment of unruptured brain aneurysms in patients with type 2 diabetes.

Improved clinical outcomes
GLP-1 RA use was associated with better results after endovascular brain aneurysm treatment in diabetic patients

What the researchers found

GLP-1 receptor agonist use was associated with improved clinical outcomes following endovascular treatment of unruptured intracranial aneurysms in type 2 diabetes patients.

Why it matters

Brain aneurysm treatment carries risks of complications. If GLP-1 drugs provide neuroprotection during and after these procedures, they could improve outcomes for the millions of diabetic patients with aneurysms.

The numbers in context

6,824 patients met criteria. 447 per group after propensity matching. No short/mid-term mortality differences. Long-term mortality significantly lower in GLP-1RA users.

How the study worked

Retrospective cohort study using the TriNetX multicenter database, comparing outcomes in T2D patients with unruptured intracranial aneurysms who used GLP-1 RAs versus those who did not.

Who was studied

T2D patients with unruptured intracranial aneurysms treated endovascularly

What this study cannot tell us

Retrospective observational study — cannot prove causation. GLP-1 RA users may differ from non-users in health-seeking behaviors and overall health status.

How to read the evidence

Large retrospective database study — provides a meaningful signal but cannot establish causation. Prospective studies would be needed for definitive conclusions.

When this study was published

Published in 2025, exploring a novel neuroprotective application of GLP-1 drugs in cerebrovascular procedures.

The bigger picture

This adds to mounting evidence that GLP-1 drugs have neuroprotective effects relevant to real-world brain procedures, beyond their established metabolic and cardiovascular benefits.

Questions still open

What specific neuroprotective mechanisms of GLP-1 RAs contribute to better aneurysm treatment outcomes?
Should GLP-1 RA status be considered in pre-procedural planning for brain aneurysm treatment?

Common questions

Can GLP-1 drugs protect the brain?

Growing evidence suggests yes. GLP-1 receptors are present in the brain, and these drugs have anti-inflammatory and neuroprotective properties. This study found that GLP-1 RA use was associated with better outcomes after brain aneurysm treatment.

Should I start a GLP-1 drug before brain aneurysm treatment?

This study shows an association but does not prove that starting GLP-1 drugs specifically for this purpose would help. If you already take a GLP-1 drug for diabetes, the findings are reassuring. Discuss any treatment changes with your doctors.

Read the original research

GLP-1 Receptor Agonists and Clinical Outcomes after Endovascular Treatment of Unruptured Aneurysms in Type 2 Diabetes.

Stroke (Hoboken, N.J.), 5(6), e001933

View on PubMed ↗Publisher’s paper ↗

Citation

Perng, Pang-Shuo; Chang, Yu; Chuang, Ming-Tsung; Wong, Chia-En; Sun, Yuan-Ting; Wang, Hao-Kuang; Chi, Kuan-Yu; Lee, Jung-Shun; Wang, Liang-Chao; Huang, Chih-Yuan. (2025). GLP-1 Receptor Agonists and Clinical Outcomes after Endovascular Treatment of Unruptured Aneurysms in Type 2 Diabetes.. Stroke (Hoboken, N.J.), 5(6), e001933. https://doi.org/10.1161/SVIN.125.001933